PDCD1 and cancer: The admission of immune checkpoint inhibitors [e.g., anti-programmed cell death-1/programmed cell death ligand 1 (PD-1/PD-L1) antibodies] in primary and advanced cancer had a striking effect on progressive-free survival, overall survival, and objective response rates on various types of cancer (6–9).